Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 9Other hematologic neoplasm 8Plasma cell 6Gastrointestinal 6Myeloid 5CNS 5Genitourinary 4Breast 4Dermatologic 3Thoracic 2Sarcoma 2Endocrine 2Other solid neoplasm 1NET 1Classical hematology 1

Conditions

Somatostatinoma 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Insulinoma 1Glucagonoma 1

Interventions

Everolimus 10lanreotide 4Capecitabine 4pasireotide 3lutetium Lu 177 dotatate 3lenvatinib 3fosbretabulin 3Temozolomide 3Sorafenib 3Paclitaxel 3Octreotide 3Nivolumab 3Magnetic Resonance Spectroscopy 3Filgrastim 3Erlotinib Hydrochloride 3Doxorubicin 3trifluridine tipiracil drug combination 2surufatinib 2pembrolizumab 2pegfilgrastim 2gallium Ga 68 dotatate 2durvalumab 2dactolisib 2Surveys and Questionnaires 2Surgical Procedures, Operative 2Sunitinib 2Rosiglitazone 2Radiotherapy 2Panobinostat 2Mitotane 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Panobinostat × Endocrine × Clear all
NCT00985946 2019-12-09

Study of Panobinostat in Patients With Neuroendocrine Tumors

University of Wisconsin, Madison

Phase 2 Terminated
15 enrolled 11 charts
EndocrineNET

Neuroendocrine Tumors

NCT01056601 2017-12-28

Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy

Masonic Cancer Center, University of Minnesota

Phase 2 Terminated
7 enrolled 8 charts
EndocrineGastrointestinal

Glucagonoma, Insulinoma, Pancreatic Neoplasms, Somatostatinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡